Stage IIA Prostate Cancer Terminated Phase 1 Trials for Motexafin lutetium (DB05296)

IndicationStatusPhase
DBCOND0028878 (Stage IIA Prostate Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00005067Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate CancerTreatment